Industry News
NCCN introduces a New Payer Resource
NCCN has introduced a Payer Relations Resource Page, which provides information on the intended use of…
Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) announces FDA approval
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Mar. 25, 2026– Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD)…
AstraZeneca announces a new FDA approval for new treatment regimen for CALQUENCE® (acalabrutinib)
Astrazeneca is pleased to announce that the US Food and Drug Administration (FDA) has approved…